Skip to main content
Equibles
MGNX logo

MGNX · Macrogenics Inc · Metrics

Track MGNX — free

Use MGNX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research MGNX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$2.29 -0.03 (-1.29%) At close · Nov 12 Q2 2024 earnings call transcript
Russell 2000 member Rebalance outlook locked
Market Cap
$146.35M
Shares
63.91M
Volume · Nov 12 894.63K Avg daily vol (3M) 716.16K

MGNX metrics

86 of 125 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$2.29
Market cap
$146.35M

Price action

23 metrics
Price change (1W)
+0.4%
Price change (30D)
-32.2%
Price change (3M)
-42.3%
Price change (6M)
-32.8%
Price change (YTD)
+44.1%
Price change (1Y)
+52.6%
Trailing year
Price change (5Y)
-88.4%
52-week high
$4.86
52-week low
$1.33
Change from 52-week high
-52.3%
Change from 52-week low
+74.4%
Annualized volatility
91.8%
Annualized volatility (3M)
95.8%
Implied volatility (30D)
108.0%
IV rank (1Y)
—
IV percentile (1Y)
—
Beta
0.9
RSI (14D)
34.5
Price vs SMA 50
-32.0%
Price vs SMA 200
-32.6%
Avg volume (3M)
707,619
Relative volume
0.6
Average dollar volume
$2.32M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
63.91M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
0.8×
reciprocal yield 123.9%
P / book
3.4
reciprocal yield 29.0%
FCF yield
-44.4%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-9.9%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
6.0×
reciprocal yield 16.5%
EV / revenue historical average (5Y)
8.1×
reciprocal yield 12.4%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-05-20

Profitability

9 metrics
Gross margin
100.0%
Operating margin
-18.7%
Trailing 12 months
Net margin
-8.0%
Gross profit (TTM)
$149.50M
Operating profit (TTM)
−$34.28M
Net income (TTM)
−$14.59M
Trailing 12 months
Diluted EPS (TTM)
$-0.23
FCF margin
-35.8%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$2.89
Gross profit per diluted share (TTM)
$2.36
Operating profit per diluted share (TTM)
$-0.54
EBITDA per diluted share (TTM)
$-0.45
Net income per diluted share (TTM)
$-0.23
Operating cash flow per diluted share (TTM)
$-1.00
Free cash flow per diluted share (TTM)
$-1.03
Capital expenditures per diluted share (TTM)
$0.03
R&D per diluted share (TTM)
$2.22
Stock compensation per diluted share (TTM)
$0.17
Book value per share
$0.88

Growth

11 metrics
Revenue growth YoY
+378.0%
Year over year
Net income growth YoY
—
Revenue (TTM)
$183.05M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+0.7%
Year over year · more shares
Revenue CAGR (3Y)
-0.5%
Revenue CAGR (5Y)
+7.3%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-34.0%
Return on assets
-4.2%
Debt / equity
—
Current ratio
3.0
EBITDA (TTM)
−$28.39M
Free cash flow (TTM)
−$65.54M
Quick ratio
—
Interest coverage
-2.0
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$113.91M
Latest balance sheet
Cash & equivalents
$113.91M
Total assets
$345.41M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$63.72M
Capital expenditures (TTM)
$1.82M
R&D (TTM)
$140.44M
SG&A (TTM)
—
Stock compensation (TTM)
$10.83M
R&D / revenue
76.7%
Stock compensation / revenue
5.9%

Ownership (13F)

9 metrics
13F filers
122
13F filer change QoQ
+13
Institutional ownership
76.3%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
43.0%
Private-fund adviser ownership
40.4%
Active holders' share change QoQ
-1.1%
Holder tenure
13.7
Price vs estimated holder cost
+3.2%

Ownership (registered funds)

1 metrics
Index-fund ownership
9.9%

Short interest

3 metrics
Short interest
7.7%
Latest settlement · 3.9 days to cover
Days to cover
3.9d
Short-squeeze score
57 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$129,086
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1125345 CUSIP 556099109 13F (30d) 76 filings 62 filers Visit website Investor relations